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(7.2%). Forty-eight patients (90.5%) underwent complete lymphadenec-
tomy. 35 patients underwent brain metastasectomy. 18 underwent SRS. 
Results: There was no postoperative mortality and severe complica-
tions after either lung or brain surgery. Histology showed 34 adenocar-
cinomas, 16 squamous cell carcinomas, and 3 large cell lung cancers. 
15 patients (28.3%) had no evidence of lymph node mtastases (N0), 20 
patients (37.7%) had hilar metastases (N1), and 18 patients (34%) had 
mediastinal metastases (N2). The 1-,2-, 3- and 5-year overall survival 
rates were 49%,19%, 10%, and 5%, respectively. The corresponding 
data for neurosurgery group was 55%, 17%, 11%, and 6%, respectively. 
The median survival time was 13 months. For SRS group the corre-
sponding data were 44.8%, 20.9% 10.5%, and 2%, respectively. The 
median survival time was 14 months. The differences between the two 
groups were not signiﬁcant (p>0.05). In lymph node negative patients 
(N0), the overall 5-year survival rate was 10%, as compared with a 
1% survival rate in patients with lymph node metastases (N1-2). The 
difference was signiﬁcant (p<0.01). For adenocarcinomas, the 5-year 
survival rate was 5%. The correspondent data for squamous cell lung 
cancers was 3%. The difference was not signiﬁcant (p>0.05). 
Conclusion: Although the overall survival rate for patients who have 
brain metastases from NSCLC is poor, surgical resection or radiosur-
gery may prove beniﬁcial in a select group of patients with synchro-
nous brain metastases and lung cancer without lymph node metastases.
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Background: Postoperative radiation therapy (PORT) in non small cell 
lung cancer (NSCLC) remains controversial. However, involved-ﬁeld 
conformal (3D) RT has never been studied prospectively. In this study, 
we aim to assess the outcome of patients treated with involved-ﬁeld 3D 
PORT with or without chemotherapy in NSCLC.
Methods: From September 1996 to 2006, data from 75 patients treated 
with curative surgery and PORT for NSCLC were retrospectively 
analyzed. Median age was 58 years (range: 38-76). There were 5 
patients with stage I, 22 with stage II, and 48 with stage III disease. 
Pneumonectomy or lobectomy was realized in 24 (32%) and 51 (68%) 
patients, respectively. Mediastinal lymphadenectomy was performed in 
all patients. Chemotherapy was given in 15 (20%). All patients had 3D 
conformal planning. Median RT dose was 60 Gy, and CTV included 
bronchial stump and only positive nodal areas.
Results: All patients have completed full treatment. With a median 
follow-up of 55 months, 26 patients are alive without disease. Me-
dian overall survival time was 24 months, with survival rate of 35% 
at 5 years. The 5-year locoregional control and distant disease-free 
rates were 80% and 57%, respectively (Fig.1). Patients treated with 
pneumonectomy and those treated with at least 60-Gy PORT had better 
outcome (Fig.2). Grade 3 or more CTC v3.0 toxicity was observed only 
in 4 (5%) pts.
Conclusions: We conclude that involved-ﬁeld 3D conformal 60-Gy 
PORT improves locoregional control without increasing lethal toxicity. 
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Purpose: To identify clinical and dosimetric factors predicting the 
risk of radiation pneumonitis (RP) and to evaluate the value of these 
factors in patients treated by accelerated hypofractionated radiotherapy 
(AHRT) alone for non-small cell lung cancer.
Materials and Methods: Sixty-nine patients were treated with AHRT 
to median dose of 54 Gy (range, 45-60 Gy) in daily 3 Gy fractions 
over 4 weeks. Dose-volume histograms (DVH) were obtained based on 
the adjusted dose converted to biologically equivalent dose delivered 
with 2 Gy per fraction using alpha/beta ratio of 3 in linear quadratic 
model. Dosimetric parameters for total lung were obtained: mean lung 
dose (MLD), Vdose (percentage of total lung volume irradiated more 
than dose). Radiation pneumonitis (RP) was graded according to the 
Radiation Therapy Oncology Group (RTOG) Acute and Late Lung 
Morbidity Scoring Criteria. We evaluated clinical parameters (sex, age, 
performance status, weight loss, pre-RT FEV1, tumor location, stage, 
RT dose) and dosimetric parameters (MLD, V5-50 in increments of 5 
Gy) associated with the prediction of RP.
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Results: The median follow-up period was 11 months (range, 3 - 40). 
Sixteen patients developed grade 3 or more RP in 1 ~ 10 months (me-
dian 3 months) after the cessation of RT. The actuarial incidence of RP 
was 26.4% at 12 months. All dosimetric parameters were signiﬁcantly 
associated with the risk of RP by univariate analysis. V5 and V15 were 
most signiﬁcant factors (p<0.0001). The 1-year cumulative incidence 
of grade≥3 RP were 0% and 51.3% in patients with V5≤54.5% and 
V5>54.5%, 3.6% and 50.6% in patients with V15≤34% and V15>34%. 
By multivariate analysis, V15 was the only factor associated with risk 
of RP. We included only V15 in the analysis as a dosimetric factor 
because all the dosimetric factors were highly correlated each other. 
There was no clinical factor associated with the risk of RP.
Conclusion: Dosimetric parameters were valuable in predicting the 
risk of RP in patients treated by AHRT alone. For lowering the risk of 
RP in patients treated by AHRT regimens, we should make efforts to 
maintain the V5 less than 54.5 % and the V15 less than 34%.
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Purpose: Many studies for unresectable stage III non-small cell lung 
carcinoma (NSCLC) focused on patients with good performance. 
However, there were few reports for patients with poor performance 
status. We treated them with split course radiation therapy (RT) alone 
and evaluated the results.
Methods and Materials: From Jun 1996 to Mar 2004, 80 patients 
started the split course RT according to our protocol. They were con-
ﬁrmed to have unresectable stage III NSCLC with poor performance; 
performance scale „d ECOG 2. Initially they received 30 Gy of radia-
tion with 2.5 or 3 Gy per fraction to gross tumor volume (GTV). The 
tumor response was evaluated 2-3 weeks later. And the second course 
of RT was recommended for good responders: „d 50% tumor diameter 
reduction or improved distal atelectasis. The treatment related toxicity 
was evaluated also.
Results: Eleven patients did not ﬁnish the initial course of RT (3-27 
Gy) due to disease progression or personal reasons. Thirty-eight pa-
tients (55.1%) among 69 patients who completed the ﬁrst course of RT 
showed a good response. Thirty good responders received the second 
course of RT with total 51 to 60 Gy. Eight patients of them did not 
receive the second course of RT due to distant metastasis or poor per-
formance. Two-year survival rate and median survival were 14.7% and 
7 months in all patients, and 26.0% and 14 months in 30 good respond-
ers who completed the second course of RT, respectively. Five patients 
(12.8%) from 39 evaluable patients had grade III radiation esophagitis 
(N=1) or pneumonitis (N=4).
Conclusions: RT alone was tolerable modality for unresectable stage 
III NSCLC with poor performance. In addition, it was able to produce 
comparable survival results in patients who showed good response after 
the ﬁrst course RT and completed the second course of RT compared 
with patients with good performance.
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Background: Radical chemoradiotherapy is a highly effective treat-
ment for inoperable non small cell lung cancer (NSCLC). The doses 
required to achieve remission or even cure have a high incidence of 
toxicity to normal thoracic tissue. 3 dimensional conformal radiother-
apy (3DCRT) reduces this risk maintaining a lethal tumour dose. We 
report the characteristics of patients treated with combination chemo-
therapy and 3DCRT in a district hospital.
Methods: Eighteen patients (3 female aged 65.2 ± 10 years) presenting 
for treatment of inoperable NSCLC between June 2003 and June 2004 
received treatment with 3DCRT and standard chemotherapy regimes 
were subjected to retrospective analysis of computerised data and case 
notes. Record was made of patient demographics, tumour staging, 
GTV, PTV, V20 and radiotherapy dose schedule. The radiotherapy 
dose/schedule varied between 55 Gy to 72 Gy and the commonest 
prescription was a single phase 66Gy in 33 fractions given over 6.5 
weeks. Follow up was undertaken at least weekly during treatment and 
at regular intervals thereafter.
Results: Performance status ranged from 0-2 (mean 1), tumour staging 
was T 2.4 ± 1.1 N1.6 ± 1.2 M 0 ± 0, GTV 134.4 ± 71.7, PTV 504.4 
± 199.3 and V20 22 ± 6%. Progression free survival was 16.7 ± 14.8 
months. Radiation toxicity assessed by the RTOG/EORTC criteria 
included acute oesophagitis in 10 (grade 1 in 8, grade 2 in 2), acute 
pneumonitis in 1, late pneumonitis in 2. Follow up duration was 22.6 ± 
14.4 months, median survival was 23.8 months with 6 (33%) patients 
surviving over 1000 days.
Conclusion: The ﬁrst year’s experience of Dorset Cancer Centre with 
3DCRT has demonstrated the modality to be safe and effective for 
treatment of inoperable NSCLC. Signiﬁcant complications occur in 
only a minority of patients and mean progression free survival exceeds 
a year in our series.
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